Hetero bevacizumab
Bevacizumab biosimilar developed by Hetero Drugs. Reference product Avastin.
About Hetero bevacizumab
Hetero received its bevacizumab permission in India in May 2016 for bowel cancer, the second Indian company after Reliance. Hetero has since added rituximab and denosumab to its Indian biosimilar range.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Hetero bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 7 | Biocon Biologics (Jobevne / Abevmy / Krabeva), CuraTeQ Biologics (CuraTeQ bevacizumab), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab), Zydus Lifesciences (Zydus bevacizumab) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Hetero: Hetero darbepoetin alfa, Hetero denosumab, Hetero rituximab, Mabura.
Chronology
- CDSCOMay 2016CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant